Obesity

Impact of aging on long-term cardiac outcomes of true-lumen recanalized chronic total occlusions in patients with overweight/obesity

Int J Obes (Lond)Published Cohort study

Authors' conclusion

For those with true-lumen recanalized CTO, the higher risk of TVMI after successful recanalization was rather evident in patients <65 years of age and without overweight/obesity, suggesting that aging might attenuate prognostic significance of "obesity paradox" for CTO interventions.

Study context

Population
Patients with chronic total occlusion (CTO) interventions; 64.4 ± 11.3 years, 403 male422 successful true-lumen recanalization
Participants
458 patients
Exposure
Overweight/obesity vs non-obesity
  • Overweight/obesityn = 311
  • Non-obesityn = 147reference
Outcome
TLF: cardiac death, target vessel MI (TVMI), target lesion revascularization (TLR)
Follow-up
Median 40.0 (17.9-61.4) months

Main finding

As reported in the abstract

Event rates (whole cohort) · median follow-up

Cardiac death

1.9%

Target vessel myocardial infarction (TVMI)

1.9%

Target lesion revascularization (TLR)

9.2%

TLF

10.7%

Observational data: associations, not effects.

Further findings

OutcomeP value
TVMI-free survivalBorderline better with Overweight/obesityP = 0.067 by log-rank test
TVMI-free survival, age <65 yearsSignificantly better with Overweight/obesityP = 0.013 compared to non-obesity group by log-rank test

TVMI risk, non-obesity <65 years (multivariate Cox)

HR among those <65 years
11.0 (95% CI 1.1-106.0)
HR among whole patients with successful CTO recanalization
6.9 (95% CI 1.4-35.1)

Safety

Stent thrombosis · median follow-up

Stent thrombosis rate
0.5%

Original publication

Impact of aging on long-term cardiac outcomes of true-lumen recanalized chronic total occlusions in patients with overweight/obesity. Int J Obes (Lond). Published 4 September 2024. doi:10.1038/s41366-024-01623-2

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.